Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (Leukemia, (2020), 34, 7, (1751-1759), 10.1038/s41375-020-0725-0): Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (Leukemia, (2020), 34, 7, (1751-1759), 10.1038/s41375-020-0725-0)

Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK), for the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK)

Research output: Contribution to journalComment/Letter to the editorAcademic

Abstract

An amendment to this paper has been published and can be accessed via a link at the top of the paper.
Original languageEnglish
Pages (from-to)2820
Number of pages1
JournalLeukemia
Volume34
Issue number10
Early online date2020
DOIs
Publication statusPublished - 1 Oct 2020

Cite this